Date Announcement
15/09/2020 2020 Annual Report to shareholders
15/09/2020 Appendix 4G and Corporate Governance Statement
10/09/2020 CDY Engages Advisers to Facilitate Divestment from Lyramid
27/08/2020 Appendix 4E and FY20 Financial Report
27/08/2020 FY20 Financial Results
27/08/2020 FY20 Results Presentation
28/07/2020 Cellmid signed exclusive agreement with premium salon distributor in the USA
22/07/2020 Cellmid Appendix 4C-Q4 FY2020 Business Activity
09/07/2020 ASX Aware query
09/07/2020 Cellmid signs exclusive agreement for SARS-CoV-2 laboratory tests
07/07/2020 Market release – Pause in trading
05/07/2020 Extension of Wondfo Sars-coV-2 rapid test distribution agreement
23/06/2020 Appendix 3Y – Change of Director’s Interest Notice
18/06/2020 Appendix 2A – Application for quotation of +securities
18/06/2020 Appendix 3G – Notification of issue, conversion or payment up of equity +securities
18/06/2020 Appendix 3Y – Change of Director’s Interest Notice
18/06/2020 Appendix 3Y – Change of Director’s Interest Notice
18/06/2020 Form 604 – Notice of change of interests of substantial holder
16/06/2020 Cellmid reports on strong QVC sales event
15/06/2020 Cellmid reports on results of the Doherty Institute testing
04/06/2020 Cellmid signs introducer agreement to broaden product offering
01/06/2020 Cellmid appoints Dr Dominic Burg as Chief Operating Officer
22/05/2020 General Meeting – May 2020
22/05/2020 Results of May 2020 General Meeting
15/05/2020 Company update and extension of voluntary suspension
14/05/2020 Amendment to notice of general meeting
11/05/2020 Cellmid Limited (ASX: CDY) – Suspension from Official Quotation
07/05/2020 Cellmid Limited (ASX: CDY) – Trading Halt
07/05/2020 Pause in Trading
04/05/2020 Appendix 2A – Application for quotation of +securities
04/05/2020 Cellmid share purchase plan completed
30/04/2020 Cellmid’s Alopecia patent allowed in Australia and Japan
27/04/2020 Cellmid Appendix 4C – Q3 FY2020 business activity
22/04/2020 Independent test results for the Wondfo Sars-Cov2 Test
22/04/2020 Notice of May 2020 General Meeting
16/04/2020 Share Purchase Plan
14/04/2020 Appendix 2A – Application for quotation of +securities
14/04/2020 Cellmid’s shipment of Sars-Cov2 test received
14/04/2020 Market Release – Pause in Trading
08/04/2020 An offer of +securities under a +securities purchase plan
07/04/2020 Cellmid Limited (ASX: CDY) – Reinstatement to Official Quotation
07/04/2020 Cellmid share placement raises $6 million
07/04/2020 Total number of +securities proposed to be issued for a placement or other type of issue
06/04/2020 Cellmid Limited (ASX: CDY) – Suspension from Official Quotation
01/04/2020 Cellmid Limited (ASX: CDY) – Trading Halt
28/03/2020 Cellmid Signs COVID-19 Rapid Diagnostic Supply Agreement
28/03/2020 Market Update on COVID-19
28/03/2020 Reinstatement to Official Quotation
06/03/2020 New Distribution channels to drive revenue growth from 2H FY2020
04/03/2020 Appendix 3G – Notification of issue, conversion or payment up of equity +securities
27/02/2020 1H FY2020 Financial Results
04/02/2020 Cellmid’s evolis patent to be granted in China
29/01/2020 Cellmid Limited notes to the Appendix 4C
06/01/2020 Key Midkine Antibody Patents granted in the US and Europe

 

 

Shop évolis®

Join our CORONAVIRUS Antibody study

Diagnosed with CORONAVIRUS?
We are looking for volunteers to help us study the body’s long term immune response to infection.
>> Sign up to express your interest